News & Updates
Filter by Specialty:
Etanercept biosimilar demonstrates long-term safety, efficacy in rheumatoid arthritis
YLB113, a biosimilar of the reference product etanercept, appears to be safe for long-term treatment of patients with rheumatoid arthritis, with efficacy sustained for up to 96 weeks, according to a study. Notably, the biosimilar is associated with fewer cases of injection-site reactions and injection-site erythema compared with the reference.
Etanercept biosimilar demonstrates long-term safety, efficacy in rheumatoid arthritis
14 Jan 2023
Coeliac disease tied to higher risk of juvenile idiopathic, rheumatoid arthritis
Young patients with coeliac disease (CD) tend to develop juvenile idiopathic arthritis (JIA) three times more often than does the general population, while adult CD patients appear to have rheumatoid arthritis (RA) nearly twice as often, reveals a study.
Coeliac disease tied to higher risk of juvenile idiopathic, rheumatoid arthritis
26 Dec 2022
Antirheumatic drugs confer cardioprotection, too
Treatments used in rheumatoid arthritis, called disease-modifying antirheumatic drugs, can also lower the risk of heart disease among patients, as shown in a recent study.
